Naprod Life Sciences issued a statement on its commitment to uninterrupted access to platinum-based oncology medicines, as industry-wide constraints around platinum-based raw materials affect the availability of Cisplatin and Carboplatin, two widely used chemotherapy injectables.
Per the company’s statement, Naprod’s focus remains on strengthening supply continuity, supporting healthcare institutions, and contributing to industry-wide efforts to find sustainable solutions that support both patient care and medicine accessibility.
Why it matters
Cisplatin and carboplatin are cornerstone platinum-based chemotherapy agents, and their global supply has been subject to periodic raw-material and manufacturing pressures. For a manufacturer whose Tarapur site runs dedicated sterile oncology injectable lines, supply-continuity commitments speak to manufacturing capacity and raw-material sourcing rather than to any clinical claim.
This statement describes manufacturing and supply matters only. It makes no claim regarding the safety or efficacy of any product. It is a company statement published on Naprod’s official LinkedIn page, presented here as a company update rather than an independently verified news report.